药物治疗能否改善SNOT-22各领域评分?临床重要差异分析
结果显示SNOT-22总量表平均MCID为8.0,各领域MCID与既往内镜鼻窦手术(ESS)患者报告值相近;尽管CAMT后总量表评分变化超过MCID,但各领域评分改善均未超过相应MCID阈值。
要点
- CAMT患者SNOT-22总量表平均MCID为8.0,与ESS历史值相近。
- 各领域MCID:鼻科3.9、鼻外鼻科2.5、耳/面部3.3、心理3.4、睡眠2.9。
- CAMT后总量表评分变化超MCID,但各领域改善均未超阈值。
核心结论
- SNOT-22总量表及领域MCID在CAMT患者中与ESS历史值相似,提示MCID独立于治疗方式选择。
- 尽管CAMT后SNOT-22总量表评分变化具有统计学意义并超过MCID,但平均各领域评分改善未达临床可辨别程度。
研究设计与样本
- 收集基线和治疗后SNOT-22问卷,采用四种基于分布的方法(半标准差、Cohen's d、测量标准误、最小可检测变化)计算MCID范围。
主要发现
- SNOT-22总量表平均MCID为8.0。
- 鼻科、鼻外鼻科、耳/面部、心理、睡眠领域平均MCID分别为3.9、2.5、3.3、3.4、2.9。
- CAMT后SNOT-22总量表评分变化超过MCID,但各领域平均评分改善均未超过相应MCID阈值。
关键数值与推荐
- SNOT-22总量表MCID=8.0;鼻科领域MCID=3.9;鼻外鼻科领域MCID=2.5;耳/面部领域MCID=3.3;心理领域MCID=3.4;睡眠领域MCID=2.9。
临床怎么用
- 解读CAMT患者SNOT-22评分变化时,应采用本研究得出的MCID值判断临床意义。
- CAMT后总量表评分改善虽超MCID,但各领域改善未达MCID,提示需关注领域特异性变化。
局限性
- 研究为观察性队列,样本来自学术转诊门诊,可能存在选择偏倚。
- 未报告随访时长、应答率及混杂因素控制等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Minimum clinically important differences (MCIDs) for the 22-item SinoNasal Outcomes Test (SNOT-22) in patients with chronic rhinosinusitis (CRS) electing endoscopic sinus surgery (ESS) are well described. However, similar estimations for the MCID have not been investigated for patients electing continued appropriate medical therapy (CAMT). We sought to determine MCID values for a medically treated CRS cohort and compare them to historical MCIDs associated with ESS. STUDY DESIGN: Prospective observational cohort study. METHODS: One hundred twenty patients with refractory CRS electing CAMT were prospectively enrolled from academic referral clinics into an observational cohort study. Baseline and posttreatment SNOT-22 survey responses were collected. Four distribution-based methods for calculating MCIDs (e.g., half-standard deviation, Cohen's d, standard error of measurement, and minimum detectable change) were used to identify a range of MCID values for SNOT-22 total and domain scores. RESULTS: The average MCID value for SNOT-22 total scores was 8.0, whereas mean MCID values for rhinologic, extranasal rhinologic, ear/facial, psychological, and sleep symptom domain scores were 3.9, 2.5, 3.3, 3.4, and 2.9, respectively, comparable to previously reported values for patients electing ESS. Although change in SNOT-22 total scores following CAMT exceeded the MCID, none of the average SNOT-22 domain score improvements surpassed their respective MCID thresholds. CONCLUSIONS: MCID values for SNOT-22 total and domain scores in patients electing CAMT are similar to previously published MCID values associated with ESS, indicating that MCID values are independent of treatment modality selection. Therefore, despite evidence of statistical significance, CAMT for CRS may not be associated with clinically discernable improvements in average SNOT-22 domain scores. LEVEL OF EVIDENCE: 2c Laryngoscope, 129:31-36, 2019.
引用
- Chowdhury NI, Mace JC, Bodner TE, et al. Does Medical Therapy Improve SinoNasal Outcomes Test-22 Domain Scores? An Analysis of Clinically Important Differences. Laryngoscope. 2018. PMID: 30208209. doi:10.1002/lary.27470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。